ClinicalTrials.gg

Program

ponsegromab

Also written as “PF-06946860” and “Ponsegromab”.

In Pfizer's pipeline, Growth Differentiation Factor 15 (GDF15) monoclonal antibody. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Cachexia, led by Pfizer.

Furthest: phase 3, since May 7, 20258 company-led studies, 2 open or runningNext primary completion: Jan 23, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer82 open or runningphase 3since May 7, 2025Jul 17, 2018Jan 23, 2028phase 3 · NCT06989437
  • Named in Pfizer’s own pipeline as ponsegromab PF-06946860, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2018First study: phase 1 study in HealthyFirst studyNCT03599063 · 63 enrolled · United States
  2. Jun 3, 2019Phase 1 study in HealthyNCT03974776 · 8 enrolled · United States
  3. Feb 19, 2020Phase 1 study in CachexiaNCT04299048 · 11 enrolled · United States
  4. Mar 15, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04803305 · 18 enrolled · United States, Canada
  5. Aug 12, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05546476 · 187 enrolled · United States, Australia, Bulgaria and more
  6. Jan 5, 2023Phase 1 study in HealthyNCT05685264 · 18 enrolled · China
  7. May 7, 2025Phase 3 study in CachexiaNCT06989437 · 982 planned · United States, Australia, Belgium and more
  8. Jun 17, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07663630 · 80 planned · United States, China

Ahead

  1. Jan 23, 2028Primary completion: phase 3 study in CachexiaNCT06989437
  2. May 6, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07663630

TargetBeta

“Growth Differentiation Factor 15 (GDF15) monoclonal antibody”the company's pipeline, read by Claude · source
“A monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), with potential anti-cachexia activity. Upon administration, ponsegromab targets and binds to GDF15, thereby preventing the binding of GDF15 to its receptor glial-cell-derived neurotrophic factor (GDN…”NCIt, read by Claude
“A monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), ”NCIt, by rule

Other programs on GDF15

ProgramCompanyFurthest phaseStudies
visugromabrulecatalym-gmbhphase 36
rilogrotugruleLG Chemphase 33

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07663630Carcinoma, Non-Small-Cell Lung · United States, China1Not yet recruitingMay 6, 202880
NCT06989437Cachexia · United States, Australia, Belgium and more3RecruitingJan 23, 2028982
NCT05685264Healthy · China1CompletedJul 7, 202318
NCT05546476Carcinoma, Non-Small-Cell Lung · United States, Australia, Bulgaria and more2CompletedMar 13, 2024187
NCT04803305Carcinoma, Non-Small-Cell Lung · United States, Canada1CompletedApr 14, 202218
NCT04299048Cachexia · United States1CompletedMar 30, 202211
NCT03974776Healthy · United States1CompletedJan 10, 20208
NCT03599063Healthy · United States1CompletedSep 18, 201963

How it is read

Names in the registry

  • “PF-06946860”, 4 entries
  • “ponsegromab”, 3 entries
  • “Ponsegromab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.